Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches

Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.

New iRECIST Oncologic Response Criteria already in clinical use at the University Medical Center – Tübingen, Germany

Shortly following the release of the new iRECIST- oncologic response criteria (Lancet Oncology, March 2017) the University Medical Center in Tübingen, Germany had already begun to implement this new response criteria into their clinical routine using mint LesionTM. The iRECIST guidelines are intended to provide a standard approach to the evaluation of solid tumors with measurements and assessment of the disease burden in trials where an immunotherapy is used.

PD Dr. Bernhard Klumpp who provides radiological response evaluation of of studies is one of the first radiologists to apply the new iRECIST response assessment in mint LesionTM. “The possibility of transferring the existing report process to an iRECIST process is of course sensational. For this a new measurement is not necessary, one simply changes perspective during observation of the process. Moreover, special features of iRECIST are indicated in the application”, says Dr. Klumpp.

The new iRECIST response evaluation platform is now available for all mint LesionTM Users. iRECIST is expected to be widely applied in both routine radiology evaluation as well as for application as a standardized response assessment methodology as required in oncology clinical trials.

Related Resources

Related Resources

Study Analyzing the Tumor Growth Rate as a Prognostic Biomarker in Lymphoma Patients Under CAR T-Cell Therapy

University Hospital Munich (LMU): Study Analyzing the Tumor Growth Rate as a Prognostic Biomarker in Lymphoma Patients Under CAR T-Cell Therapy

A recent study[1] conducted by researchers at the University Hospital Munich (LMU) investigated the role of tumor growth rate (TGR) in predicting the…

A picture of a person looking at a brain scan and the interface of mint Lesion™  on a computer

Advancing Neuro-Oncology Assessments: Mint Medical to Integrate Newly Published RANO 2.0 Criteria into mint Lesion™

Glioblastomas and other gliomas are the most common malignant primary brain tumor types, yet few effective therapies are available. Clinical research…

A person looking at MRI and CT scans on a  computer

Study Discovers Overdiagnosis of Progressive Cancer in Routine Clinical Evaluations

A recent retrospective study led by Dr. Marilyn J. Siegel and her team at the Washington University School of Medicine in St. Louis has shed light on…